

Robert G Maki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7110627/publications.pdf>

Version: 2024-02-01

459
papers

45,923
citations

2215

99
h-index

1980

206
g-index

478
all docs

478
docs citations

478
times ranked

33160
citing authors

#	ARTICLE	IF	CITATIONS
1	Anaplastic Lymphoma Kinase Inhibition in Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 1693-1703.	27.0	4,141
2	A framework for advancing our understanding of cancer-associated fibroblasts. <i>Nature Reviews Cancer</i> , 2020, 20, 174-186.	28.4	2,012
3	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. <i>Nature Medicine</i> , 2000, 6, 991-997.	30.7	1,945
4	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009, 373, 1097-1104.	13.7	1,233
5	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	13.7	1,144
6	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-1-S-41.	4.9	1,004
7	Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033. <i>Journal of Clinical Oncology</i> , 2008, 26, 626-632.	1.6	951
8	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1493-1501.	10.7	921
9	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011, 12, 1004-1012.	10.7	847
10	Crizotinib in <i>ALK</i> -Rearranged Inflammatory Myofibroblastic Tumor. <i>New England Journal of Medicine</i> , 2010, 363, 1727-1733.	27.0	769
11	Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. <i>Clinical Cancer Research</i> , 2005, 11, 4182-4190.	7.0	768
12	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	28.9	738
13	Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5352-5359.	1.6	693
14	Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 2824-2831.	1.6	681
15	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. <i>Journal of Clinical Oncology</i> , 2007, 25, 2755-2763.	1.6	655
16	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 786-793.	1.6	647
17	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010, 42, 715-721.	21.4	642
18	Consensus meeting for the management of gastrointestinal stromal tumorsâ€“ Report of the GIST Consensus Conference of 20â€“21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005, 16, 566-578.	1.2	628

#	ARTICLE	IF	CITATIONS
19	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	13.7	610
20	Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 3133-3140.	1.6	522
21	A novel <i>WWTR1</i> – <i>CAMTA1</i> gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 644-653.	2.8	445
22	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). <i>Cancer</i> , 2008, 112, 608-615.	4.1	437
23	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 1045-1052.	10.7	430
24	Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2011, 6, 942-946.	1.1	407
25	Advances in sarcoma genomics and new therapeutic targets. <i>Nature Reviews Cancer</i> , 2011, 11, 541-557.	28.4	364
26	Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors. <i>Journal of Clinical Oncology</i> , 2010, 28, 835-840.	1.6	362
27	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)–Update of the NCCN Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, S-1-S-29.	4.9	360
28	A 14-Year Retrospective Review of Angiosarcoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 241-247.	2.0	350
29	Novel V600E BRAF mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 853-859.	2.8	329
30	High prevalence of <i>CIC</i> fusion with double homeobox (DUX4) transcription factors in <i>EWSR1</i> –negative undifferentiated small blue round cell sarcomas. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 207-218.	2.8	307
31	Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 3154-3160.	1.6	295
32	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4541-4547.	1.6	293
33	Consistent <i>MYC</i> and <i>FLT4</i> gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 25-33.	2.8	291
34	Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate. <i>New England Journal of Medicine</i> , 2006, 354, 2006-2013.	27.0	289
35	Sorafenib for Advanced and Refractory Desmoid Tumors. <i>New England Journal of Medicine</i> , 2018, 379, 2417-2428.	27.0	287
36	Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 1480-1490.	1.6	280

#	ARTICLE	IF	CITATIONS
37	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. <i>Nature</i> , 2010, 467, 849-853.	27.8	279
38	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. <i>Nature Medicine</i> , 2007, 13, 748-753.	30.7	275
39	Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. <i>Annals of Surgery</i> , 2007, 245, 347-352.	4.2	273
40	Extraskeletal myxoid chondrosarcoma. <i>Cancer</i> , 2008, 113, 3364-3371.	4.1	272
41	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. <i>International Journal of Cancer</i> , 2002, 100, 623-626.	5.1	262
42	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017, 30, 1433-1442.	5.5	261
43	Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2014, 19, 193-201.	3.7	258
44	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1563-1570.	1.6	252
45	<i>KDR</i> Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors. <i>Cancer Research</i> , 2009, 69, 7175-7179.	0.9	247
46	Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 7135-7142.	1.6	244
47	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	2.8	243
48	Gastrointestinal Stromal Tumors in Children and Young Adults. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 179-187.	0.6	239
49	Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis. <i>Clinical Cancer Research</i> , 2011, 17, 4082-4090.	7.0	237
50	Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3204-3215.	7.0	233
51	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. <i>Annals of Oncology</i> , 2017, 28, 2595-2605.	1.2	229
52	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	4.1	222
53	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma. <i>Cancer Research</i> , 2007, 67, 6626-6636.	0.9	217
54	Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. <i>Clinical Cancer Research</i> , 2010, 16, 4884-4891.	7.0	213

#	ARTICLE	IF	CITATIONS
55	Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. <i>Journal of Clinical Oncology</i> , 2009, 27, 3148-3153.	1.6	210
56	Classification and Subtype Prediction of Adult Soft Tissue Sarcoma by Functional Genomics. <i>American Journal of Pathology</i> , 2003, 163, 691-700.	3.8	207
57	Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2007, 13, 2643-2650.	7.0	202
58	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5 Suppl 2, S1-29; quiz S30.	4.9	201
59	Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. <i>Clinical Cancer Research</i> , 2004, 10, 3282-3290.	7.0	194
60	Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4985-4995.	1.6	190
61	Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma. <i>Annals of Surgery</i> , 2007, 246, 105-113.	4.2	187
62	Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. <i>Annals of Oncology</i> , 2004, 15, 1667-1672.	1.2	184
63	Advanced chondrosarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2013, 24, 2916-2922.	1.2	184
64	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 8862-8867.	7.1	179
65	A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib. <i>Journal of the National Cancer Institute</i> , 2008, 100, 282-284.	6.3	174
66	Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5484-5492.	1.6	173
67	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1424-1431.	1.6	172
68	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2013, 14, 371-382.	10.7	171
69	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. <i>Journal of Clinical Investigation</i> , 2007, 117, 3248-3257.	8.2	167
70	Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). <i>Cancer</i> , 2010, 116, 2258-2265.	4.1	163
71	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology, The</i> , 2016, 17, 1261-1271.	10.7	161
72	A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients. <i>Clinical Cancer Research</i> , 2008, 14, 8191-8197.	7.0	160

#	ARTICLE	IF	CITATIONS
73	Tumor-specific cell surface expression of the -KDEL containing endoplasmic reticular heat shock protein gp96. , 1996, 69, 340-349.		159
74	A phase 2 trial of R1507, a monoclonal antibody to the insulinâ€like growth factorâ€1 receptor (IGFâ€1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. Cancer, 2014, 120, 2448-2456.	4.1	158
75	Evidence-Based Recommendations for Local Therapy for Soft Tissue Sarcomas. Journal of Clinical Oncology, 2007, 25, 1003-1008.	1.6	156
76	Patientâ€derived xenografts for individualized care in advanced sarcoma. Cancer, 2014, 120, 2006-2015.	4.1	154
77	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma, 2013, 2013, 1-8.	1.3	151
78	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Journal of Clinical Oncology, 2016, 34, 3898-3905.	1.6	151
79	Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. Annals of Surgery, 2013, 258, 422-429.	4.2	150
80	Adjuvant therapy for highâ€grade, uterusâ€limited leiomyosarcoma. Cancer, 2013, 119, 1555-1561.	4.1	150
81	Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. Journal of Clinical Oncology, 2004, 22, 4567-4574.	1.6	149
82	Sorafenib Inhibits the Imatinib-Resistant <i>KIT</i> <i>T670I</i> Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	7.0	144
83	Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence. Journal of the American College of Surgeons, 2012, 215, 53-59.	0.5	141
84	Stress-Induced Proteins in Immune Response to Cancer. Current Topics in Microbiology and Immunology, 1991, 167, 109-123.	1.1	141
85	Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii35-ii38.	1.2	138
86	Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 5658-5662.	7.1	134
87	Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncology, The, 2007, 8, 513-524.	10.7	133
88	Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure. Clinical Cancer Research, 2009, 15, 5902-5909.	7.0	133
89	The Impact of Chemotherapy on the Survival of Patients With High-grade Primary Extremity Liposarcoma. Annals of Surgery, 2004, 240, 686-697.	4.2	132
90	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. European Journal of Cancer, 2012, 48, 3036-3044.	2.8	129

#	ARTICLE	IF	CITATIONS
91	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	1.6	126
92	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 170-181.	7.0	118
93	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012, 118, 3330-3336.	4.1	118
94	Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. <i>Journal of Clinical Oncology</i> , 2009, 27, 3509-3509.	1.6	118
95	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2012, 23, 1601-1607.	1.2	117
96	Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 1875-1884.	1.6	113
97	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor. <i>JAMA Oncology</i> , 2018, 4, e184060.	7.1	112
98	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1044.	1.6	108
99	Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2007, 14, 134-142.	1.5	104
100	Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas. <i>Cancer</i> , 2012, 118, 5878-5887.	4.1	103
101	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020, 31, 1506-1517.	1.2	103
102	Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii89-ii93.	1.2	101
103	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. <i>Oncolmmunology</i> , 2020, 9, 1747340.	4.6	101
104	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	1.6	101
105	Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 2501-2501.	1.6	101
106	New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 534-542.	6.4	99
107	Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2010, 28, 3-3.	1.6	98
108	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. <i>Cancer</i> , 2003, 98, 832-840.	4.1	97

#	ARTICLE	IF	CITATIONS
109	Pleomorphic Characteristics of a Germ-Line KIT Mutation in a Large Kindred with Gastrointestinal Stromal Tumors, Hyperpigmentation, and Dysphagia. <i>Clinical Cancer Research</i> , 2004, 10, 1250-1254.	7.0	97
110	Phase II study of the HSP90-inhibitor BII021 in gastrointestinal stromal tumors. <i>Annals of Oncology</i> , 2013, 24, 252-257.	1.2	97
111	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 210-217.	2.8	97
112	The miRâ€17â€92 cluster and its target <i>THBS1</i> are differentially expressed in angiosarcomas dependent on <i>MYC</i> amplification. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 569-578.	2.8	96
113	Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future. <i>Oncologist</i> , 2007, 12, 999-1006.	3.7	89
114	A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1964-1972.	2.3	89
115	Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma. <i>JAMA Oncology</i> , 2019, 5, 254.	7.1	89
116	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. <i>European Journal of Cancer</i> , 2011, 47, 1006-1012.	2.8	88
117	Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2011, 18, 328-336.	1.5	88
118	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring <i>KIT</i> A502-3ins Mutation: An <i>In vitro</i> Mutagenesis Screen for Drug Resistance. <i>Clinical Cancer Research</i> , 2009, 15, 6862-6870.	7.0	86
119	The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2638-2647.	7.0	85
120	Role of Interleukin 12 and Costimulators in T Cell Anergy <i>In Vivo</i> . <i>Journal of Experimental Medicine</i> , 1997, 186, 1119-1128.	8.5	84
121	Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. <i>European Journal of Cancer</i> , 2015, 51, 2413-2422.	2.8	79
122	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. <i>Cancer</i> , 2005, 103, 1431-1438.	4.1	78
123	IGF2 overexpression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. <i>Journal of Pathology</i> , 2010, 221, 300-307.	4.5	78
124	Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2005, 23, 9011-9011.	1.6	78
125	Preliminary Results of High-Dose Single-Fraction Radiotherapy for the Management of Chordomas of the Spine and Sacrum. <i>Neurosurgery</i> , 2013, 73, 673-680.	1.1	77
126	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 877-886.	10.7	75

#	ARTICLE	IF	CITATIONS
127	Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 2044-2046.	1.1	73
128	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. <i>JAMA Oncology</i> , 2017, 3, 944.	7.1	73
129	Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 25-43.	2.3	71
130	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012, 30, 1193-1202.	2.6	71
131	Development and clinical application of an integrative genomic approach to personalized cancer therapy. <i>Genome Medicine</i> , 2016, 8, 62.	8.2	71
132	A Developmental Model of Sarcomagenesis Defines a Differentiation-Based Classification for Liposarcomas. <i>American Journal of Pathology</i> , 2008, 172, 1069-1080.	3.8	65
133	Sarcomas. <i>Pediatric Clinics of North America</i> , 2015, 62, 179-200.	1.8	65
134	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11015-11015.	1.6	65
135	Why Do Patients with Low-Grade Soft Tissue Sarcoma Die?. <i>Annals of Surgical Oncology</i> , 2008, 15, 3550-3560.	1.5	64
136	First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. <i>European Journal of Cancer</i> , 2012, 48, 547-563.	2.8	64
137	Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2008, 26, 10502-10502.	1.6	64
138	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. <i>European Journal of Cancer</i> , 2015, 51, 1611-1617.	2.8	63
139	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	3.7	62
140	Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. <i>Journal of Clinical Oncology</i> , 2018, 36, 210-216.	1.6	62
141	Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. <i>Journal of Clinical Oncology</i> , 2006, 24, 9502-9502.	1.6	62
142	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 309-319.	2.3	61
143	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019, 32, 1772-1785.	5.5	61
144	A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 6704-6711.	7.0	59

#	ARTICLE	IF	CITATIONS
145	Age-Stratified Risk of Unexpected Uterine Sarcoma Following Surgery for Presumed Benign Leiomyoma. <i>Oncologist</i> , 2015, 20, 433-439.	3.7	59
146	Chemotherapy in clear cell sarcoma. <i>Medical Oncology</i> , 2011, 28, 859-863.	2.5	58
147	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. <i>Annals of Surgical Oncology</i> , 2012, 19, 1551-1559.	1.5	57
148	Protocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 165-170.	2.5	57
149	Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. <i>British Journal of Cancer</i> , 2013, 109, 1717-1724.	6.4	55
150	Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Oncology</i> , 2018, 29, 857-871.	1.2	55
151	A Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients with Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2002, 7, 531-538.	3.7	54
152	Toward Better Soft Tissue Sarcoma Staging: Building on American Joint Committee on Cancer Staging Systems Versions 6 and 7. <i>Annals of Surgical Oncology</i> , 2013, 20, 3377-3383.	1.5	52
153	Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10006-10006.	1.6	52
154	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017, 146, 531-537.	1.4	51
155	Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10009-10009.	1.6	51
156	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	51
157	Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity. <i>Cancer</i> , 2007, 110, 2050-2060.	4.1	50
158	Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. <i>Sarcoma</i> , 2015, 2015, 1-7.	1.3	49
159	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. <i>Targeted Oncology</i> , 2013, 8, 211-213.	3.6	47
160	<i>TERT</i> promoter mutations in solitary fibrous tumour. <i>Histopathology</i> , 2018, 73, 843-851.	2.9	47
161	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Cancer</i> , 2019, 125, 2610-2620.	4.1	47
162	New Therapeutic Targets in Soft Tissue Sarcoma. <i>Advances in Anatomic Pathology</i> , 2012, 19, 170-180.	4.3	45

#	ARTICLE	IF	CITATIONS
163	NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)—expansion and update of NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2 Suppl 1, S-1-26; quiz 27-30.	4.9	45
164	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702	1.2	44
165	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. Annals of Oncology, 2013, 24, 1924-1930.	1.2	43
166	Evaluation of the rate constant for the reaction OH+H2CO: Application of modeling and sensitivity analysis techniques for determination of the product branching ratio. Journal of Chemical Physics, 1989, 91, 4088-4097.	3.0	41
167	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. Journal of Clinical Oncology, 2015, 33, 1849-1854.	1.6	41
168	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports, 2019, 9, 14551.	3.3	41
169	Structure-Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors. Journal of Medicinal Chemistry, 1997, 40, 1955-1968.	6.4	40
170	International expert opinion on patient-tailored management of soft tissue sarcomas. European Journal of Cancer, 2014, 50, 679-689.	2.8	40
171	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Annals of Oncology, 2013, 24, 537-542.	1.2	39
172	Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. Journal of Medicinal Chemistry, 1987, 30, 2137-2144.	6.4	38
173	Management of Soft Tissue Sarcoma. , 2013, , .		38
174	Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. Journal of Clinical Oncology, 2018, 36, 194-201.	1.6	38
175	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature Cell Biology, 2019, 21, 203-213.	10.3	38
176	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology, 2004, 22, 3001-3001.	1.6	38
177	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028-A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 11006-11006.	1.6	37
178	EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. Sarcoma, 2008, 2008, 1-6.	1.3	36
179	Cascades of transcriptional induction during human lymphocyte activation. European Journal of Cell Biology, 2001, 80, 321-328.	3.6	35
180	De Novo Osteogenic Sarcoma in Patients Older Than Forty. Clinical Orthopaedics and Related Research, 2005, &NA;, 110-115.	1.5	34

#	ARTICLE	IF	CITATIONS
181	Primary Angiosarcoma of Bone. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 528-534.	1.3	34
182	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. Frontiers in Oncology, 2015, 5, 186.	2.8	34
183	The intricate interplay among body weight, stress, and the immune response to friend or foe. Journal of Clinical Investigation, 2003, 111, 183-185.	8.2	34
184	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. British Journal of Cancer, 2019, 120, 1026-1032.	6.4	33
185	The enantio- and diastereoselective synthesis of the first phospho-statine derivative. Tetrahedron Letters, 1986, 27, 2337-2340.	1.4	32
186	A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas. Sarcoma, 2006, 2006, 1-4.	1.3	32
187	Pediatric sarcomas occurring in adults. Journal of Surgical Oncology, 2008, 97, 360-368.	1.7	32
188	Angiosarcomas and Other Sarcomas of Endothelial Origin. Hematology/Oncology Clinics of North America, 2013, 27, 975-988.	2.2	32
189	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology, 2017, 35, 11008-11008.	1.6	32
190	Lyman-alpha. photometry: curve of growth determination, comparison to theoretical oscillator strength, and line absorption calculations at high temperature. The Journal of Physical Chemistry, 1985, 89, 4815-4821.	2.9	31
191	Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94. Somatic Cell and Molecular Genetics, 1993, 19, 73-81.	0.7	30
192	Clinical Activity of Pazopanib in Metastatic Extrasosseous Ewing Sarcoma. Rare Tumors, 2015, 7, 86-88.	0.6	30
193	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Annals of Oncology, 2018, 29, 1995-2002.	1.2	30
194	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. Journal of Bone and Joint Surgery - Series A, 2019, 101, 1309-1318.	3.0	30
195	Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.. Journal of Clinical Oncology, 2010, 28, 2596-2596.	1.6	30
196	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. Journal of Clinical Oncology, 2017, 35, 11005-11005.	1.6	30
197	The Activity of Sunitinib against Gastrointestinal Stromal Tumor Seems to be Distinct from Its Antiangiogenic Effects: Fig. 1.. Clinical Cancer Research, 2006, 12, 6203-6204.	7.0	29
198	Sarcomas With Spindle Cell Morphology. Seminars in Oncology, 2009, 36, 324-337.	2.2	28

#	ARTICLE	IF	CITATIONS
199	Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec [®]). <i>Leukemia Research</i> , 2010, 34, 827-829.	0.8	28
200	Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 1582-1590.	6.4	26
201	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015, 20, 823-830.	3.7	26
202	Treatment of soft tissue sarcoma: a focus on earlier stages. <i>Future Oncology</i> , 2017, 13, 13-21.	2.4	26
203	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10503-10503.	1.6	26
204	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11001-11001.	1.6	26
205	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2508-2508.	1.6	26
206	Soft tissue sarcoma as a model disease to examine cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2001, 13, 270-274.	2.4	25
207	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	4.1	25
208	Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 13-17.	0.8	24
209	Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. <i>Annals of Oncology</i> , 2012, 23, 2205-2206.	1.2	24
210	Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. <i>Leukemia Research</i> , 2013, 37, 790-794.	0.8	24
211	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2019, 120, 132-139.	2.8	24
212	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.	1.6	24
213	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015, 51, 852-860.	2.8	23
214	Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. <i>Current Problems in Surgery</i> , 2003, 40, 144-193.	1.1	23
215	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA10502-LBA10502.	1.6	22
216	Role of chemotherapy in patients with soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 229-236.	2.4	21

#	ARTICLE	IF	CITATIONS
217	A context dependent role for Wnt signaling in tumorigenesis and stem cells. <i>Cell Cycle</i> , 2008, 7, 720-724.	2.6	21
218	Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults. <i>JAMA Oncology</i> , 2016, 2, 941.	7.1	21
219	Benign Mesenchymal Stromal Cells in Human Sarcomas. <i>Clinical Cancer Research</i> , 2010, 16, 5630-5640.	7.0	20
220	DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). <i>Journal of Clinical Oncology</i> , 2006, 24, 9522-9522.	1.6	20
221	A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 10503-10503.	1.6	20
222	A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13600-e13600.	1.6	20
223	Mechanisms of Sarcomagenesis. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 427-449.	2.2	19
224	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb004) in metastatic soft tissue sarcomas. <i>Cancer</i> , 2019, 125, 2445-2454.	4.1	19
225	Future directions for immunotherapeutic intervention against sarcomas. <i>Current Opinion in Oncology</i> , 2006, 18, 363-368.	2.4	17
226	CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 186-195.	2.8	17
227	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10514-10514.	1.6	17
228	Ifosfamide in the Neoadjuvant Treatment of Osteogenic Sarcoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2033-2035.	1.6	16
229	Novel <i>HMG2A-YAP1</i> fusion gene in aggressive angiomyxoma. <i>BMJ Case Reports</i> , 2019, 12, e227475.	0.5	16
230	Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study) Tj ETQq0 0 0 rBT /Overlock 10 Tf	1.6	16
231	A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).. <i>Journal of Clinical Oncology</i> , 2010, 28, 10004-10004.	1.6	16
232	Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). <i>Annals of Oncology</i> , 2019, 30, v683.	1.2	15
233	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2019, 24, 857-863.	3.7	15
234	Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. <i>Journal of Clinical Oncology</i> , 2008, 26, 10531-10531.	1.6	15

#	ARTICLE	IF	CITATIONS
235	A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).. Journal of Clinical Oncology, 2015, 33, 10503-10503.	1.6	15
236	A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2016, 34, 11016-11016.	1.6	15
237	Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab. BMJ Case Reports, 2020, 13, e234363.	0.5	14
238	Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. Journal of Clinical Oncology, 2006, 24, 9503-9503.	1.6	14
239	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. Journal of Clinical Oncology, 2014, 32, 10520-10520.	1.6	14
240	Role of interleukin 12 and costimulators in T cell anergy in vivo. Journal of Experimental Medicine, 2009, 206, 1207-1207.	8.5	13
241	Treatment of Adult Soft Tissue Sarcoma: Old Concepts, New Insights, and Potential for Drug Discovery. Cancer Investigation, 2012, 30, 300-308.	1.3	13
242	Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. Targeted Oncology, 2013, 8, 295-300.	3.6	13
243	Consumptive Coagulopathy in Angiosarcoma: A Recurrent Phenomenon?. Sarcoma, 2014, 2014, 1-7.	1.3	13
244	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. BMC Cancer, 2019, 19, 593.	2.6	13
245	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARCO24 Study. Oncologist, 2020, 25, e1655-e1662.	3.7	13
246	Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. Journal of Clinical Oncology, 2008, 26, 10533-10533.	1.6	13
247	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. Journal of Clinical Oncology, 2011, 29, 10000-10000.	1.6	13
248	O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1547-1552.	2.2	12
249	Recent advances in therapy for gastrointestinal stromal tumors. Current Oncology Reports, 2007, 9, 165-169.	4.0	12
250	Other Targetable Sarcomas. Seminars in Oncology, 2009, 36, 358-371.	2.2	12
251	Management of Soft Tissue Sarcoma. , 2016, , .		12
252	Perspectives for immunotherapy in endocrine cancer. Endocrine-Related Cancer, 2016, 23, R469-R484.	3.1	12

#	ARTICLE	IF	CITATIONS
253	A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. <i>Clinical Cancer Research</i> , 2018, 24, 4968-4975.	7.0	12
254	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. <i>Future Oncology</i> , 2020, 16, 4289-4301.	2.4	12
255	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. <i>Journal of Clinical Oncology</i> , 2014, 32, 10508-10508.	1.6	12
256	SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10578-TPS10578.	1.6	12
257	Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma. <i>JAMA Oncology</i> , 2022, 8, 740.	7.1	12
258	SELNET clinical practice guidelines for bone sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103685.	4.4	12
259	Immunity against soft-tissue sarcomas. <i>Current Oncology Reports</i> , 2003, 5, 282-287.	4.0	11
260	A case of high-risk penile epithelioid hemangioendothelioma. <i>Nature Reviews Urology</i> , 2009, 6, 223-227.	3.8	11
261	Squamous Cell Carcinoma of the Oral Tongue in Two Patients Previously Exposed to Long-Term Pegylated Liposomal Doxorubicin. <i>Oncologist</i> , 2012, 17, 1594-1595.	3.7	11
262	A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). <i>Journal of Clinical Oncology</i> , 2006, 24, 9514-9514.	1.6	11
263	A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 9515-9515.	1.6	11
264	Metastatic epithelioid hemangioendothelioma (EHE): Role of systemic therapy and survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 10079-10079.	1.6	11
265	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	1.6	11
266	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019, 125, 4435-4441.	4.1	10
267	Multiplexed Evaluation of Microdosed Antineoplastic Agents <i>In Situ</i> in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 3958-3968.	7.0	10
268	Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. <i>Biochemistry</i> , 1988, 27, 1111-1116.	2.5	9
269	Therapeutic impact of ET-743 (Yondelis; trabectedin), a new marine-derived compound, in sarcoma. <i>Current Opinion in Orthopaedics</i> , 2003, 14, 419-428.	0.3	9
270	New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents. <i>Clinical Cancer Research</i> , 2012, 18, 5837-5844.	7.0	9

#	ARTICLE	IF	CITATIONS
271	Targeting sarcoma tumor-initiating cells through differentiation therapy. <i>Stem Cell Research</i> , 2017, 21, 117-123.	0.7	9
272	Impact of Intraoperative Molecular Imaging after Fluorescent-Guided Pulmonary Metastasectomy for Sarcoma. <i>Journal of the American College of Surgeons</i> , 2022, 234, 748-758.	0.5	9
273	Management Dilemmas Due to a Paratracheal Follicular Dendritic Cell Tumor. <i>Annals of Thoracic Surgery</i> , 2006, 82, 1898-1900.	1.3	8
274	Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis. <i>Sarcoma</i> , 2009, 2009, 1-5.	1.3	8
275	Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 807-818.	4.2	8
276	Title is missing!., 2017, , .		8
277	Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 9001-9001.	1.6	8
278	Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10021-10021.	1.6	8
279	Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4-4.	1.6	8
280	The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10508-10508.	1.6	8
281	Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11009-11009.	1.6	8
282	Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, e13510-e13510.	1.6	8
283	Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i> : A Multi-institutional Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 4092-4104.	7.0	8
284	Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. <i>Leukemia and Lymphoma</i> , 2007, 48, 2071-2074.	1.3	7
285	Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial. <i>Annals of Oncology</i> , 2012, 23, xi20.	1.2	7
286	Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. <i>Frontiers in Oncology</i> , 2013, 3, 9.	2.8	7
287	Efficacy of sorafenib in patients with desmoid-type fibromatosis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11065-11065.	1.6	7
288	Problems in Colon Cancer and a Child With Renal Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5255-5256.	1.6	6

#	ARTICLE	IF	CITATIONS
289	Eribulin in soft-tissue sarcomas. <i>Lancet Oncology</i> , The, 2011, 12, 988-989.	10.7	6
290	Case Series of Dermatologic Events Associated With the Insulin-Like Growth Factor Receptor 1 Inhibitor Cixutumumab. <i>Journal of Clinical Oncology</i> , 2011, 29, e638-e640.	1.6	6
291	Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. <i>Annals of Oncology</i> , 2012, 23, 804-805.	1.2	6
292	Psychological Distress of Internal Medicine Residents Rotating on a Hematology and Oncology Ward: An Exploratory Study of Patient Deaths, Personal Stress, and Attributed Meaning. <i>Medical Science Educator</i> , 2015, 25, 413-420.	1.5	6
293	An unusual case of Kaposi sarcoma masquerading as cystitis in a kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2019, 21, e13132.	1.7	6
294	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	3.7	6
295	Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: Report of an expanded phase II trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 9010-9010.	1.6	6
296	A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10003-10003.	1.6	6
297	Multidisciplinary Management of Soft-Tissue Sarcomas. <i>Cancer Investigation</i> , 2002, 20, 818-824.	1.3	5
298	The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). <i>Clinical Sarcoma Research</i> , 2012, 2, 21.	2.3	5
299	Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. <i>Clinical Sarcoma Research</i> , 2015, 5, 21.	2.3	5
300	Surgical Management of Sarcoma Metastatic to Liver. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 57-67.	1.5	5
301	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 9013-9013.	1.6	5
302	Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).. <i>Journal of Clinical Oncology</i> , 2010, 28, 10013-10013.	1.6	5
303	Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3039-3039.	1.6	5
304	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11037-11037.	1.6	5
305	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11061-11061.	1.6	5
306	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11081-TPS11081.	1.6	5

#	ARTICLE	IF	CITATIONS
307	Ewing sarcoma and related <sc>FET</sc> family translocation-associated round cell tumors: A century of clinical and scientific progress. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 509-517.	2.8	5
308	An iterative synthesis of radiolabelled polyethylene glycol oligomers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1989, 27, 1437-1450.	1.0	4
309	3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). <i>European Journal of Cancer</i> , 2015, 51, S689.	2.8	4
310	Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 477-486.	2.2	4
311	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 501-512.	3.1	4
312	Sarcoma: The Merging of Science and Clinical Care. <i>Journal of Clinical Oncology</i> , 2018, 36, 99-100.	1.6	4
313	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST.., 2013, , .		4
314	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 9013-9013.	1.6	4
315	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 9017-9017.	1.6	4
316	Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2005, 23, 9032-9032.	1.6	4
317	Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10044-10044.	1.6	4
318	Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10537-10537.	1.6	4
319	Sarcoma. <i>Oncologist</i> , 2001, 6, 333-337.	3.7	3
320	DNA Copy Number Analysis in Gastrointestinal Stromal Tumors Using Gene Expression Microarrays. <i>Cancer Informatics</i> , 2008, 6, CIN.S387.	1.9	3
321	9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 590-591.	2.2	3
322	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012, 23, ix478-ix479.	1.2	3
323	When Benign Tumors Mimic Malignancies: A Case of Lymphangiomas Masquerading as Metastatic Disease. <i>Rare Cancers and Therapy</i> , 2013, 1, 21-27.	0.2	3
324	Definitive Local Therapy Is Associated with Improved Survival in Metastatic Soft Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 932.	3.7	3

#	ARTICLE	IF	CITATIONS
325	Sarcomas of Soft Tissue. , 2014, , 1753-1791.e10.		3
326	Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). Journal of Clinical Oncology, 2007, 25, 10061-10061.	1.6	3
327	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2015, 33, 10514-10514.	1.6	3
328	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. Journal of Clinical Oncology, 2015, 33, LBA10502-LBA10502.	1.6	3
329	Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.. Journal of Clinical Oncology, 2016, 34, 11032-11032.	1.6	3
330	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. Journal of Clinical Oncology, 2016, 34, 3086-3086.	1.6	3
331	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. Journal of Clinical Oncology, 2017, 35, 60-60.	1.6	3
332	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. Journal of Clinical Oncology, 2018, 36, 11505-11505.	1.6	3
333	Title is missing!. , 2017, , .		3
334	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. European Journal of Cancer, Supplement, 2009, 7, 590.	2.2	2
335	Targeted Therapy in Sarcoma: Should We Be Lumpers or Splitters?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 652-657.	3.8	2
336	Solitary Fibrous Tumor/Hemangiopericytoma. , 2013, , 179-184.		2
337	Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. Oncology and Therapy, 2016, 4, 1-16.	2.6	2
338	Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis. Annals of Oncology, 2017, 28, v529.	1.2	2
339	A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.. Journal of Clinical Oncology, 2021, 39, TPS11583-TPS11583.	1.6	2
340	Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma (MFH) and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf,50 142 Td		2
341	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. Journal of Clinical Oncology, 2004, 22, 9017-9017.	1.6	2
342	A putative tumor suppressor role for Wnt-signaling in sarcomagenesis. Journal of Clinical Oncology, 2006, 24, 9507-9507.	1.6	2

#	ARTICLE	IF	CITATIONS
343	Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. Journal of Clinical Oncology, 2008, 26, 10529-10529.	1.6	2
344	Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).. Journal of Clinical Oncology, 2010, 28, 10029-10029.	1.6	2
345	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	1.6	2
346	A model for multi-institutional, multidisciplinary sarcoma videoconferencing.. Journal of Clinical Oncology, 2013, 31, 10521-10521.	1.6	2
347	Fighting Cancer Through the Study of Sarcomas. American Scientist, 2005, 93, 414.	0.1	2
348	Natural History: Importance of Size, Site, and Histopathology. , 2013, , 19-35.		2
349	Benign Soft Tissue Tumors. , 2013, , 339-354.		2
350	General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy. , 2013, , 37-64.		2
351	General Description. , 2016, , 3-17.		2
352	Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDGS], histiocytic sarcoma [HS]).. Journal of Clinical Oncology, 2020, 38, e23574-e23574.	1.6	2
353	MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.. Journal of Clinical Oncology, 2022, 40, TPS11589-TPS11589.	1.6	2
354	Bluish Papule in a Middle-aged Manâ€™Quiz Case. Archives of Dermatology, 2005, 141, 1595-600.	1.4	1
355	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. Cancer Investigation, 2009, 27, 402-406.	1.3	1
356	GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. Current Cancer Therapy Reviews, 2009, 5, 100-104.	0.3	1
357	Randomization and Statistical Power: Paramount in Trial Reproducibility (Even for Rare Cancers). Oncologist, 2012, 17, 1129-1132.	3.7	1
358	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor. , 2013, , 149-160.		1
359	Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts). Annals of Oncology, 2016, 27, vii74.	1.2	1
360	Patient-derived xenografts effectively capture patient clinical responses to oncology therapy. European Journal of Cancer, 2016, 61, S203.	2.8	1

#	ARTICLE	IF	CITATIONS
361	Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database. <i>Sarcoma</i> , 2021, 2021, 1-11.	1.3	1
362	Leiomyosarcoma. , 2013, , 113-127.		1
363	Extraskeletal Osteogenic Sarcoma. , 2016, , 327-334.		1
364	Gastrointestinal Stromal Tumors. , 2016, , 77-104.		1
365	MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS. , 0, , 1070-1082.		1
366	A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 9523-9523.	1.6	1
367	Pharmacodynamic case study of sunitinib/SU11248 in a gastrointestinal stromal tumor patient: Evidence toward a mechanism of effect. <i>Journal of Clinical Oncology</i> , 2006, 24, 9526-9526.	1.6	1
368	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10021-10021.	1.6	1
369	Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS10103-TPS10103.	1.6	1
370	Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10538-10538.	1.6	1
371	Stress and empathy among internal medicine trainees on an inpatient hematology-oncology ward.. <i>Journal of Clinical Oncology</i> , 2014, 32, 231-231.	1.6	1
372	Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 3533-3533.	1.6	1
373	Systemic therapy in clear cell sarcoma.. <i>Journal of Clinical Oncology</i> , 2010, 28, 10098-10098.	1.6	1
374	Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival.. <i>Journal of Clinical Oncology</i> , 2011, 29, 10071-10071.	1.6	1
375	Desmoplastic Small Round Cell Tumor. , 2013, , 275-280.		1
376	Sarcomas More Common in Children. , 2013, , 221-250.		1
377	Clear Cell Sarcoma/Melanoma of Soft Parts. , 2013, , 267-273.		1
378	Undifferentiated Pleomorphic Sarcoma (UPS; Malignant Fibrous Histiocytoma: MFH) and Myxofibrosarcoma. , 2013, , 129-136.		1

#	ARTICLE	IF	CITATIONS
379	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. Journal of Clinical Oncology, 2013, 31, 10551-10551.	1.6	1
380	A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.. Journal of Clinical Oncology, 2015, 33, TPS10577-TPS10577.	1.6	1
381	Leiomyosarcoma. , 2016, , 125-142.		1
382	Uncommon/Unique Sites. , 2016, , 343-351.		1
383	Alveolar Soft Part Sarcoma. , 2016, , 283-289.		1
384	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. Journal of Clinical Oncology, 2018, 36, TPS11590-TPS11590.	1.6	1
385	Gastrointestinal Stromal Tumors (GIST) and Their Management. Gastrointestinal Cancer Research: GCR, 2007, 1, S81-4.	0.7	1
386	A phase I/III study of DX-8951f and gemcitabine in advanced solid tumour malignancies. European Journal of Cancer, 2002, 38, S46-S47.	2.8	0
387	Sarcomas of Soft Tissue. , 2002, , 197-203.		0
388	The Influence of Older Age on Outcome in Soft Tissue Sarcoma of the Extremity. International Journal of Radiation Oncology Biology Physics, 2005, 63, S51.	0.8	0
389	Bluish Papule in a Middle-aged Manâ€™Diagnosis. Archives of Dermatology, 2005, 141, 1595.	1.4	0
390	Sarcomas. Hematology/Oncology Clinics of North America, 2005, 19, xi-xii.	2.2	0
391	CYP3A4/5 and pharmacogenetics in patients with sarcoma â€™ Authors' reply. Lancet Oncology, The, 2007, 8, 668-669.	10.7	0
392	Introduction: The 2008 European Society for Medical Oncology International Symposium on Sarcomas and Gastrointestinal Stromal Tumors. Seminars in Oncology, 2009, 36, 289.	2.2	0
393	How Do I Treat Patients with Metastatic Soft Tissue Sarcoma?. Oncology Times, 2012, 34, 12-14.	0.1	0
394	Targeting HDM2 (Human MDM2) in Sarcomas. Annals of Oncology, 2012, 23, ix54.	1.2	0
395	Brain Metastases(BM) in Patients (PTS) with Soft Tissue and Bone Sarcoma (Sarcoma): A Retrospective Study of 107 Pts. Annals of Oncology, 2012, 23, ix489.	1.2	0
396	General Description. , 2013, , 1-17.		0

#	ARTICLE	IF	CITATIONS
397	Synovial Sarcoma. , 2013, , 137-147.		0
398	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. Expert Opinion on Orphan Drugs, 2014, 2, 653-664.	0.8	0
399	364 A summary score to assess toxicity of small molecule oral kinase inhibitors (SMOKIs) in randomized clinical trials (RCTs). European Journal of Cancer, 2015, 51, S75.	2.8	0
400	Chromosome 9p21 Amplification in HNSCC Is Associated With Increased Mortality Following Adjuvant Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, S144.	0.8	0
401	3436 Efficacy and safety of trabectedin (T) or dacarbazine (D) for treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. European Journal of Cancer, 2015, 51, S700.	2.8	0
402	1321 Efficacy and safety of trabectedin (T) or dacarbazine (D) in an elderly patient subgroup (65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior chemotherapy. European Journal of Cancer, 2015, 51, S194.	2.8	0
403	Fibrosarcoma and Its Variants. , 2016, , 203-219.		0
404	Mostly Benign/Rarely Metastasizing. , 2016, , 355-367.		0
405	Selected Benign Tumors. , 2016, , 369-386.		0
406	Subgroup analysis of leiomyosarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. European Journal of Cancer, 2017, 72, S155.	2.8	0
407	Fighting Cancer Through the Study of Sarcomas. American Scientist, 2005, 93, 414.	0.1	0
408	Molecular profiling of liposarcoma subtypes. Journal of Clinical Oncology, 2005, 23, 9016-9016.	1.6	0
409	Abstract C250: The pericyte as a novel stromal element and therapeutic target in sarcoma. , 2009, , .		0
410	Abstract LB-62: Direct visualization of circulating sarcoma cells by whole-blood fluorescence in-situ hybridization. , 2010, , .		0
411	Direct visualization of circulating sarcoma cells by whole-blood fluorescence in situ hybridization.. Journal of Clinical Oncology, 2010, 28, 10637-10637.	1.6	0
412	Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST). Blood, 2010, 116, 2276-2276.	1.4	0
413	Genome-wide analysis and characterization of an online sarcoma cohort.. Journal of Clinical Oncology, 2012, 30, 10097-10097.	1.6	0
414	Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors.. Journal of Clinical Oncology, 2012, 30, 10022-10022.	1.6	0

#	ARTICLE	IF	CITATIONS
415	How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas.. Journal of Clinical Oncology, 2012, 30, 10001-10001.	1.6	0
416	Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.. Journal of Clinical Oncology, 2012, 30, 10013-10013.	1.6	0
417	Advanced soft-tissue sarcoma in patients over age 75: Patterns of care and survival.. Journal of Clinical Oncology, 2012, 30, 10057-10057.	1.6	0
418	Alveolar Soft Part Sarcoma. , 2013, , 259-265.		0
419	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis). , 2013, , 161-177.		0
420	Gastrointestinal Stromal Tumors (GISTs). , 2013, , 67-91.		0
421	Other Uterine Sarcomas. , 2013, , 289-299.		0
422	Extraskeletal Myxoid Chondrosarcoma. , 2013, , 281-287.		0
423	Vascular Sarcomas. , 2013, , 201-213.		0
424	Mostly Benign/Rarely Metastasizing Soft Tissue Tumor. , 2013, , 329-337.		0
425	Radiation-Induced Sarcomas. , 2013, , 251-257.		0
426	Sustentacular Tumors of Lymph Tissue. , 2013, , 309-315.		0
427	Liposarcoma. , 2013, , 93-111.		0
428	Uterine Sarcomas in the Elderly. , 2013, , 319-348.		0
429	Linking kinases to adverse events through kinase inhibitors.. Journal of Clinical Oncology, 2013, 31, e13524-e13524.	1.6	0
430	Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).. Journal of Clinical Oncology, 2015, 33, 10561-10561.	1.6	0
431	Abstract 5589: Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. , 2015, , .		0
432	Sarcomas More Common in Children. , 2016, , 243-274.		0

#	ARTICLE	IF	CITATIONS
433	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor. , 2016, , 165-176.		0
434	Radiation-Induced Sarcoma. , 2016, , 275-281.		0
435	Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis). , 2016, , 177-194.		0
436	Solitary Fibrous Tumor/Hemangiopericytoma. , 2016, , 195-201.		0
437	Extraskeletal Myxoid Chondrosarcoma. , 2016, , 307-313.		0
438	Liposarcoma. , 2016, , 105-124.		0
439	Other Uterine Sarcomas. , 2016, , 315-326.		0
440	Reactive Lesions. , 2016, , 387-390.		0
441	Natural History: Importance of Size, Site, Histopathology. , 2016, , 19-40.		0
442	Desmoplastic Small Round Cell Tumor. , 2016, , 299-305.		0
443	General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy. , 2016, , 41-74.		0
444	Sustentacular Tumors of Lymph Tissue. , 2016, , 335-341.		0
445	Synovial Sarcoma. , 2016, , 153-163.		0
446	Clear Cell Sarcoma/Melanoma of Soft Parts. , 2016, , 291-297.		0
447	Vascular Sarcomas. , 2016, , 221-236.		0
448	Visualizing toxicity: A single score to summarize toxicity in randomized clinical trials.. Journal of Clinical Oncology, 2016, 34, 6605-6605.	1.6	0
449	Sarcoma tumor size (T) staging: Are radiology or pathology measurements more appropriate?. Journal of Clinical Oncology, 2017, 35, e22522-e22522.	1.6	0
450	Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. Journal of Clinical Oncology, 2017, 35, e22516-e22516.	1.6	0

#	ARTICLE	IF	CITATIONS
451	A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21158-e21158.	1.6	0
452	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. Journal of Clinical Oncology, 2018, 36, e23570-e23570.	1.6	0
453	Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).. Journal of Clinical Oncology, 2018, 36, 11513-11513.	1.6	0
454	Evaluation and Management of Sarcomas. , 2018, , .		0
455	Abstract 2155: High-plex spatial profiling analysis of multidrug CIVO microdose studies in cancer patients. , 2019, , .		0
456	Comments regarding lung metastasis surgery for sarcoma. Oncology, 2011, 25, 1210-1.	0.5	0
457	Lenalidomide and the expanding toolkit to manage Kaposi sarcoma. Clinical Cancer Research, 2022, , .	7.0	0
458	Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. Cancer Research, 2022, 82, CT235-CT235.	0.9	0
459	A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1.. Journal of Clinical Oncology, 2022, 40, TPS11586-TPS11586.	1.6	0